Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 2/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.43 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.41 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.41 |
| ▸ | TPH1 | P17752 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1938140 | 1.00 | SLC7A5 (0.56) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL8020635 | 0.97 | SLC7A5 (0.59) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL8020641 | 0.97 | SLC7A5 (0.59) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL4279625 | 0.95 | SLC7A5 (0.61) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL321221 | 0.95 | SLC7A5 (0.61) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL525092 | 0.91 | SLC7A5 (0.53) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL525094 | 0.91 | SLC7A5 (0.53) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL8333097 | 0.89 | SLC7A5 (0.54) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL8333110 | 0.89 | SLC7A5 (0.54) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL27680265 | 0.87 | SLC7A5 (0.67) | SLC7A5TAAR1SLC6A2ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2332583-B1 | ANTIVIRAL DISINFECTANTS AND THEIR APPLICATIONS | GOJO IND INC (US) | 2018-12-19 | — | — | EP | claimed |
| US-20130237598-A1 | ANTIVIRAL COMPOSITIONS | GOJO INDUSTRIES, INC. (US) | 2013-09-12 | — | — | US | claimed |
| US-8450378-B2 | Antiviral method | GOJO INDUSTRIES, INC. (US) | 2013-05-28 | — | — | US | claimed |
| EP-2332583-A1 | Antiviral disinfectants and their applications | Gojo Industries, Inc. (US) | 2011-06-15 | — | — | EP | claimed |
| US-20090018213-A1 | ANTIVIRAL METHOD | SILVER POINT FINANCE, LLC, AS COLLATERAL AGENT | 2009-01-15 | — | — | US | claimed |
| EP-2332583-B1 | ANTIVIRAL DISINFECTANTS AND THEIR APPLICATIONS | GOJO IND INC (US) | 2018-12-19 | — | — | EP | disclosed |
| US-9707162-B2 | Microbicidal personal care compositions comprising metal ions | RECKITT & COLMAN (OVERSEAS) LIMITED (GB) | 2017-07-18 | — | — | US | disclosed |
| US-20160158122-A1 | Microbicidal Personal Care Compositions Comprising Metal Ions | RECKITT & COLMAN (OVERSEAS) HEALTH LIMITED (GB) | 2016-06-09 | — | — | US | disclosed |
| EP-2925125-A1 | MICROBICIDAL PERSONAL CARE COMPOSITIONS COMPRISING METAL IONS | Reckitt & Colman (Overseas) Limited (GB) | 2015-10-07 | — | — | EP | disclosed |
| EP-2471559-B1 | Antiviral method | GOJO IND INC (US) | 2014-11-26 | — | — | EP | disclosed |
| WO-2014083330-A1 | MICROBICIDAL PERSONAL CARE COMPOSITIONS COMPRISING METAL IONS | RECKITT & COLMAN (OVERSEAS) LIMITED (GB) | 2014-06-05 | — | — | WO | disclosed |
| US-20130237598-A1 | ANTIVIRAL COMPOSITIONS | GOJO INDUSTRIES, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-8450378-B2 | Antiviral method | GOJO INDUSTRIES, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| EP-2471559-A2 | Antiviral method | Gojo Industries, Inc. (US) | 2012-07-04 | — | — | EP | disclosed |
| EP-2332583-A1 | Antiviral disinfectants and their applications | Gojo Industries, Inc. (US) | 2011-06-15 | — | — | EP | disclosed |
| US-20090018213-A1 | ANTIVIRAL METHOD | SILVER POINT FINANCE, LLC, AS COLLATERAL AGENT | 2009-01-15 | — | — | US | disclosed |
| EP-2012838-A2 | ANTIVIRAL DISINFECTANTS AND APPLICATIONS | Gojo Industries, Inc. (US) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007095008-A2 | ANTIVIRAL DISINFECTANTS AND APPLICATIONS | GOJO INDUSTRIES, INC. (US) | 2007-08-23 | — | — | WO | disclosed |
| US-20070185216-A1 | ANTIVIRAL METHOD | PNC BANK, NATIONAL ASSOCIATION, AS AGENT | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158122-A1 | Microbicidal Personal Care Compositions Comprising Metal Ions | POLR1C, SOD1, CUTA | SLC7A5 4176/4885TAAR1 991/4885SLC6A2 4724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.